Keywords: astrazeneca, submits, snda, seroquel, treatment, depression, bipolar

AstraZeneca submits sNDA for Seroquel as treatment for depression in bipolar disorder

Article | 09 January 2006

Print This

Anglo-Swedish drug major AstraZeneca has submitted a supplemental New Drug Application to the US Food and Drug Administration to seek ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in